Skip to main content
Toggle Menu of ADA WebSites
ADA Websites
Partnerships and Commissions
Toggle Search Area
Toggle Menu
e-mail Print Share

New FAQ on restrictions for hydrocodone combination products

October 09, 2014 Learn more about how new restrictions on hydrocodone combination products could impact dentists and their practices in a new frequently asked questions article on the ADA Center for Professional Success.

Effective Oct. 6, the Drug Enforcement Administration began reclassifying hydrocodone combination products, which include opioids such as Vicodin, Lorcet, Lortab and Norco, as Schedule II substances. The DEA said the reclassification will protect public health and safety by reducing the potential for abuse, dependence and diversion of the highly addictive substances, while still ensuring that they're available to patients with a legitimate medical need and who have an ongoing consultation with their health care professional.

After hearing from a number of members with questions about the reclassification, the ADA published a second frequently asked questions section on the ADA Center for Professional Success. To read the original ADA News story covering the DEA's decision, visit and search the ADA News September archives for "DEA Imposes Tighter Restrictions on Hydrocodone Combination Products."